查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2001117

肺癌免疫療法查核點抑制劑市場：2026-2032年全球市場預測（按癌症類型、通路、治療方法、作用機制、治療階段和最終用戶分類）

Immune Checkpoint Inhibitors for Lung Cancer Market by Cancer Type, Distribution Channel, Treatment Regimen, Mechanism Of Action, Line Of Therapy, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，肺癌免疫查核點抑制劑市場價值將達到 13.2 億美元，到 2026 年將成長到 15.2 億美元，到 2032 年將達到 35.5 億美元，複合年成長率為 15.08%。

主要市場統計數據
基準年 2025 13.2億美元
預計年份：2026年 15.2億美元
預測年份：2032年 35.5億美元
複合年成長率 (%) 15.08%

本報告概述了臨床進展、相關人員的優先事項和關鍵決策點，介紹了肺癌免疫查核點抑制劑的策略背景。

免疫查核點抑制劑從根本上改變了肺癌的治療模式，使治療策略從單純的細胞毒性療法轉向以靶向免疫調節為導向、旨在帶來持續臨床獲益的療法。在過去十年間，臨床醫生和研究人員加深了對腫瘤與免疫系統相互作用的理解，並將這些發現應用於治療，激活抗腫瘤免疫，從而改善了許多患者的生存和生活品質。

我們將找出正在重塑肺癌免疫療法的變革性變化，包括基於生物標記的治療、聯合治療以及監管和保險公司的趨勢。

目前，肺癌免疫療法正經歷多項相互促進的變革，這些變革正在改變治療方法的研發、評估和實施方式。首先，臨床實踐正朝著精準免疫腫瘤學的方向發展，基於生物標記（例如PD-L1表達和更廣泛的基因組特徵）的選擇正成為治療方法選擇和臨床試驗入組決策的關鍵因素。因此，適應性隊列和基於生物標記的篩選組正擴大被納入臨床試驗設計，以提高訊號檢測的準確性並加快監管決策。

評估 2025 年美國新關稅措施對肺癌免疫療法的供應鏈、臨床計畫和商業性取得的累積影響。

影響跨境貿易的政策可能會對整個藥物研發和商業化生態系統產生連鎖反應。提案的2025年關稅調整將為免疫查核點抑制劑計畫帶來複雜的營運和經濟挑戰。進口生物材料、特殊試劑或成品的關稅增加可能會推高產品單價，迫使製造商重新評估其籌資策略和契約製造關係。為此，申辦方可能會加快供應鏈在地化進程，重新談判長期供應商協議，或實現供應商多元化，以降低單一來源的風險。

我們分析癌症類型、通路、治療方法、作用機制、治療線和最終用戶等方面的見解，以最佳化市場定位。

在肺癌這一高度多樣化的領域，深入了解肺癌的細分對於最佳化研發和商業化策略至關重要。就癌症類型而言，非小細胞肺癌和小細胞肺癌之間的差異會影響臨床試驗的設計、監管終點和製劑方案。在非小細胞肺癌中，非鱗狀細胞癌和鱗狀細胞癌的組織學差異決定了預期療效和安全性。此外，非鱗狀細胞癌內部的亞型細分，例如腺癌和大細胞癌，揭示了生物標記的普遍性以及與標靶治療的潛在相互作用。

美洲、歐洲、中東和非洲以及亞太地區的優先事項和不同的部署路徑，影響產品的取得和商業化。

臨床實務、監管方式和醫療基礎設施的區域差異對免疫查核點抑制劑的引入和應用產生了顯著影響。在美洲，完善的醫保報銷管道、強大的腫瘤網路和高水平的臨床試驗能力支持新治療方法的快速推廣，但成本控制和支付方對療效的嚴格審查仍然是持續的挑戰。該地區的市場進入策略通常結合可靠的III期臨床試驗證據和真實世界臨床數據，以確保藥物被納入醫保覆蓋範圍並獲得有利的准入政策。

根據公司層面的洞察，競爭考察和合作洞察是決定肺癌免疫療法領域領導地位的關鍵因素。

肺癌免疫療法領域的企業策略正朝著幾個共同的方向發展：差異化的臨床定位、策略聯盟、產品組合的廣度以及實證醫學能力。優先發展強大的生物標記計畫和建立伴隨診斷聯盟的企業，能夠更好地掌握臨床定義的、療效最為顯著的亞群人群。投資於聯合治療研究並有效管理早期安全性訊號的企業，則能夠顯著區別於單藥療法。

產業領導者為加速免疫療法的發展、擴大應用範圍以及建立強大的商業和臨床管道而提​​出的實用建議。

產業領導者可以透過推動一系列切實可行且優先的措施來加速發展並降低商業化風險。首先，透過將研發項目組合與生物標記定義的適應症相匹配，並儘早開發伴隨核准策略，簡化法規核准流程並改善患者篩選。同時，設計包含適應性要素和以病人為中心的有意義終點的聯合治療試驗，以展現超越傳統生存指標的價值。其次，投資於分散式和混合式臨床試驗模式，以產生更具代表性的真實世界數據，從而擴大受試者招募範圍、提高受試者保留率並支持與支付方的對話。

一套嚴謹的調查方法，詳細說明了用於產生可靠市場資訊的證據來源、專家參與、三角驗證和限制。

本報告的分析整合了多種證據來源，得出嚴謹而令人信服的結論。二次研究包括同行評審的臨床文獻、監管指導文件和公開的臨床實驗室註冊數據，揭示了治療機制、安全性概況和實驗室設計。為了補充這些資訊來源，我們也對腫瘤學家、臨床實驗室醫生、衛生經濟學專家、監管專家和供應鏈負責人進行了結構化訪談，以了解實際應用經驗和營運挑戰。

對肺癌免疫療法領域的相關人員，從臨床創新、政策轉變和營運重點中獲得的策略見解進行了具體化的總結。

科學創新、策略性商業化策略和不斷變化的政策正在改變肺癌治療中免疫查核點抑制劑的研發和應用。臨床上，儘管基於生物標記的患者篩選和聯合治療正在改善治療效果，但安全性管理和實驗室設計方面也出現了新的複雜性。在營運上，分銷管道的選擇和終端用戶的接受度會影響藥物的可及性，而穩健的供應鏈對於維持治療的連續性至關重要，即使面臨政策變化也能確保治療的持續性。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 工業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：肺癌免疫查核點抑制劑市場：依癌症類型分類

  • 癌症
    • 非小細胞肺癌
      • 非鱗狀
      • 腺癌
      • 大細胞癌
      • 鱗狀上皮
    • 小細胞肺癌

第9章：肺癌免疫療法查核點抑制劑市場：依分銷管道分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房
  • 專科藥房

第10章：肺癌免疫查核點抑制劑市場：依治療方法

  • 聯合治療
    • 合併化療
    • 聯合標靶治療治療
  • 單藥治療

第11章 肺癌免疫療法查核點抑制劑市場：依作用機制分類

  • CTLA-4抑制劑
  • PD-1抑制劑
    • 半原發
    • Nivolumab
    • Pembrolizumab

第12章 肺癌免疫查核點抑制劑市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第13章 肺癌免疫療法查核點抑制劑市場：依最終用戶分類

  • 門診手術中心
  • 居家照護設施
  • 醫院
  • 腫瘤診所

第14章 肺癌免疫療法查核點抑制劑市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章：肺癌免疫療法查核點抑制劑市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 肺癌免疫療法查核點抑制劑市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國肺癌免疫查核點抑制劑市場

第18章：中國肺癌免疫查核點抑制劑市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • AstraZeneca plc
  • Bayer AG
  • BeyondSpring Pharmaceuticals Inc.
  • BioLineRx Ltd.
  • BridgeBio Inc.
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • F. Hoffmann-La Roche AG
  • Genentech, Inc.
  • IQVIA Inc.
  • Jazz Pharmaceuticals
  • Mirati Therapeutics Inc.
  • Ono Pharmaceutical Co. Ltd
  • Philogen SpA
Product Code: MRR-E40E525C3802

The Immune Checkpoint Inhibitors for Lung Cancer Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.52 billion in 2026, with a CAGR of 15.08%, reaching USD 3.55 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.52 billion
Forecast Year [2032] USD 3.55 billion
CAGR (%) 15.08%

Setting the strategic context for immune checkpoint inhibitors in lung cancer by outlining clinical advances, stakeholder priorities, and decision-making imperatives

Immune checkpoint inhibitors have fundamentally altered the treatment paradigm for lung cancer, moving therapeutic strategy from cytotoxic-only approaches to targeted immune modulation that aims to deliver durable clinical benefit. Over the past decade, clinicians and researchers have advanced our understanding of tumor-immune interactions, translating those discoveries into therapeutics that reinvigorate antitumor immunity and alter survival and quality-of-life considerations for many patients.

This introduction frames the clinical, operational, and commercial dimensions that stakeholders must weigh when evaluating immune checkpoint inhibitor programs. Clinically, integrating biomarker testing, refining patient selection, and optimizing sequencing with chemotherapy and targeted agents remain primary considerations for therapeutic teams. Operationally, the complexity of introducing biologic therapies influences distribution choices, cold-chain logistics, and infusion capacity planning across hospitals and ambulatory settings. Commercially, alignment with payers, evidence generation to support reimbursement, and differentiated positioning based on mechanism of action and line of therapy are central to adoption strategies.

As you read further, the analysis that follows synthesizes clinical progress, regulatory posture, and system-level pressures to present a balanced view of opportunities and risks. The goal is to equip decision-makers with a clear, concise foundation for prioritizing investments and partnerships that will accelerate meaningful patient impact.

Identifying transformative shifts reshaping lung cancer immunotherapy including biomarker-driven care, combination approaches, and regulatory and payer dynamics

The landscape for lung cancer immunotherapy is in the midst of several concurrent and reinforcing shifts that are changing how therapies are developed, evaluated, and delivered. First, clinical practice has moved toward precision immuno-oncology where biomarker-driven selection-such as PD-L1 expression and broader genomic signatures-informs therapeutic choice and trial enrollment. Consequently, trial designs increasingly embed adaptive cohorts and biomarker-enriched arms to improve signal detection and expedite regulatory decision-making.

Second, combination strategies are now a core development focus, pairing checkpoint inhibitors with chemotherapy, targeted agents, or other immune modulators to address resistance mechanisms and enhance response durability. These combinations require new safety management paradigms and novel clinical endpoints, which in turn influence regulatory engagement and payer evidence expectations. Third, regulatory agencies and payers are placing greater emphasis on real-world evidence and health-economic outcomes, prompting sponsors to invest in longitudinal data collection and outcomes research alongside classical randomized trials.

Fourth, manufacturing and supply chain considerations are driving investment in scalable biologics production and cold-chain logistics. At the same time, digital health tools and decentralized trial methodologies are improving patient access and retention, expanding the potential study population beyond traditional academic centers. Taken together, these shifts are creating an environment where agility in clinical strategy, data generation, and stakeholder engagement will determine which therapies achieve broad adoption and meaningful patient benefit.

Assessing the cumulative impact of new United States tariff policies in 2025 on lung cancer immunotherapy supply chains, clinical programs, and commercial access

Policy actions that affect cross-border trade can reverberate across the drug development and commercialization ecosystem, and proposed tariff changes in 2025 present a complex set of operational and economic considerations for immune checkpoint inhibitor programs. Higher duties on imported biologic materials, specialized reagents, or finished products can increase the unit cost of goods, potentially pressuring manufacturers to reevaluate sourcing strategies and contract manufacturing relationships. In response, sponsors may accelerate localization of supply chains, renegotiate long-term supplier agreements, or diversify suppliers to mitigate single-source risks.

Clinical development is sensitive to supply interruptions and cost volatility. Tariff-driven increases in the cost of clinical supplies or delays at customs can complicate trial logistics, particularly for multicenter studies that rely on synchronized drug shipments. Sponsors can mitigate this risk by building buffer inventories, qualifying multiple depots, and leveraging regional manufacturing hubs where feasible. Meanwhile, commercial access strategies may need to adapt as payers scrutinize price increases; transparent communication about cost drivers and evidence of clinical value will be critical to maintaining formulary positions.

Finally, the policy environment can incentivize strategic partnerships and vertical integration, encouraging companies to explore regional production or licensing arrangements that preserve margins and secure supply. While tariffs add a layer of complexity, proactive operational planning, scenario-based financial modeling, and early engagement with regulatory and customs authorities can reduce disruption and preserve patient access to critical immunotherapies.

Decoding segmentation-driven insights across cancer type, distribution channel, treatment regimen, mechanism, line of therapy, and end user to optimize positioning

A fine-grained understanding of segmentation is essential for tailoring development and commercialization approaches across the heterogeneous lung cancer landscape. When considering cancer type, distinctions between Non-Small Cell Lung Cancer and Small Cell Lung Cancer drive different clinical trial designs, regulatory endpoints, and prescribing patterns, while within Non-Small Cell Lung Cancer the split between Non-Squamous and Squamous histologies shapes expected responses and safety profiles. Further subclassification such as Adenocarcinoma and Large Cell Carcinoma under Non-Squamous informs biomarker prevalence and the likely interaction with targeted therapies.

Distribution channel choices-from hospital pharmacy to online pharmacy, retail pharmacy, and specialty pharmacy-determine the logistics model, patient support structures, and reimbursement pathways. The treatment regimen axis separates monotherapy from combination therapy, and when combinations include chemotherapy or targeted therapy the clinical development strategy must address additive toxicities and regimen sequencing. End user segmentation across ambulatory surgical centers, home care settings, hospitals, and oncology clinics influences site readiness, infusion capacity, and the design of patient navigation services.

Mechanism of action segmentation differentiates CTLA-4 inhibitors from PD-1 and PD-L1 inhibitors, with specific agents such as ipilimumab, cemiplimab, nivolumab, pembrolizumab, atezolizumab, and durvalumab offering distinct clinical profiles that matter for labeling and positioning. Finally, line-of-therapy distinctions between first line, second line, and third or later determine the competitive set and the evidence bar required to displace incumbents. Integrating these segmentation dimensions allows sponsors to prioritize clinical programs, channel strategies, and evidence generation to match the needs of distinct patient populations and care settings.

Regional priorities and differentiated adoption trajectories across Americas, Europe, Middle East & Africa, and Asia-Pacific that influence access and commercialization

Regional variation in clinical practice, regulatory approach, and healthcare infrastructure materially affects how immune checkpoint inhibitors are adopted and scaled. In the Americas, established reimbursement pathways, strong oncology networks, and high clinical trial capacity support rapid uptake of novel regimens, though cost containment and payer scrutiny of value remain constant considerations. Market access strategies in this region often combine robust phase III evidence with real-world outcomes to secure formulary placement and favorable utilization policies.

In Europe, Middle East & Africa, heterogeneity in regulatory frameworks and payer models requires a nuanced approach that accounts for national health technology assessment processes, variable reimbursement timelines, and differing logistical capacities. Engagement with regional health authorities and local stakeholders is essential to align clinical evidence packages with country-specific value frameworks. In Asia-Pacific, the diversity of health systems spans advanced markets with accelerated adoption to emerging markets where access constraints and infrastructure gaps necessitate adaptive distribution and patient support programs. Manufacturing localization and strategic partnerships can be especially impactful in this region to improve affordability and supply reliability.

Across all regions, tailoring evidence generation to local decision drivers, investing in clinician education, and designing flexible distribution models are core imperatives. Cross-regional coordination can unlock efficiencies in global development while allowing targeted adaptations for local regulatory and payer landscapes.

Competitive and collaborative company-level insights revealing where innovation, partnerships, and portfolio strategies will determine leadership in lung cancer immunotherapy

Company strategies in lung cancer immunotherapy are converging around several themes: differentiated clinical positioning, strategic alliances, portfolio breadth, and capabilities in evidence generation. Firms that prioritize robust biomarker programs and companion diagnostic partnerships position themselves to capture clinically defined subpopulations where therapeutic benefit is most pronounced. Companies that invest in combination science and manage early safety signals effectively can create compelling differentiation versus monotherapy options.

Strategic collaborations-ranging from research partnerships with biotechnology innovators to co-development agreements with makers of targeted agents-accelerate access to complementary mechanisms and expand clinical options for resistant disease. Firms that build integrated capabilities in real-world evidence generation, health economics, and outcomes research strengthen payer discussions and facilitate reimbursement negotiations. Meanwhile, investments in scalable biologics manufacturing and geographically diversified supply chains reduce operational risk and can support more predictable commercialization rollouts.

Competitive positioning also rests on commercial execution, with leaders offering comprehensive patient support programs, education for treating physicians, and adaptive pricing strategies that reflect value-based outcomes. Companies that combine strong clinical data with operational excellence and payor-aligned value propositions will be best placed to sustain adoption and long-term utilization across diverse care settings.

Actionable recommendations for industry leaders to accelerate development, enhance access, and build resilient commercial and clinical pathways in immunotherapy

Industry leaders can accelerate progress and de-risk commercialization by pursuing a set of actionable, prioritized initiatives. First, align R&D portfolios with biomarker-defined indications and develop companion diagnostic strategies early to streamline regulatory pathways and improve patient selection. Concurrently, design combination trials that incorporate adaptive elements and meaningful patient-centric endpoints to demonstrate value beyond traditional survival metrics. Second, invest in decentralized and hybrid trial models to broaden recruitment, enhance retention, and generate more representative real-world evidence that supports payer dialogues.

Third, fortify supply chains through supplier diversification, regional manufacturing options, and inventory strategies that reduce exposure to trade disruptions and policy shocks. Fourth, engage payers proactively with transparent value dossiers and outcomes-based contracting where appropriate to address affordability concerns while protecting access. Fifth, build differentiated patient support programs that facilitate adherence, manage immune-related adverse events, and enable treatment continuity across hospitals, oncology clinics, home care settings, and specialty pharmacies.

Finally, cultivate strategic partnerships with diagnostics firms, academic centers, and contract research organizations to accelerate translational science and speed clinical development. By implementing these recommendations, leaders will enhance the likelihood of successful product launches, sustainable access, and measurable improvements in patient outcomes.

Robust research methodology detailing evidence sources, expert engagement, triangulation methods, and limitations used to produce defensible market intelligence

The analysis underpinning this report integrates multiple evidence streams to ensure rigorous, defensible conclusions. Secondary research included peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries to map therapeutic mechanisms, safety profiles, and trial designs. To complement these sources, structured interviews were conducted with oncologists, clinical trial investigators, health economics specialists, regulatory affairs experts, and supply chain leaders to capture experiential insights and operational challenges.

Data triangulation methods linked qualitative interview findings with published evidence to validate emergent themes and identify gaps in the public record. Segmentation analyses were applied to clinical, distribution, and end-user dimensions to illuminate differentiated adoption pathways. Limitations of the methodology include the rapidly evolving nature of clinical data, regional variability in regulatory timelines, and the potential for emerging trial results to alter competitive dynamics; to mitigate these, the study highlights areas for ongoing surveillance and recommends periodic updates to maintain relevance.

Where appropriate, the methodology prioritized transparency in source selection and analytic assumptions, enabling stakeholders to assess the provenance of key findings and to adapt the approach for bespoke analyses focused on particular geographies, mechanisms, or therapeutic combinations.

Concluding synthesis that crystallizes strategic implications from clinical innovation, policy shifts, and operational priorities for lung cancer immunotherapy stakeholders

The convergence of scientific innovation, strategic commercialization tactics, and policy evolution is reshaping how immune checkpoint inhibitors are developed and used in lung cancer care. Clinically, biomarker-driven selection and combination regimens are refining therapeutic benefit while introducing new complexities for safety management and trial design. Operationally, distribution channel choice and end-user readiness influence access, and resilient supply chains are essential to preserve continuity of care in the face of policy shocks.

From a strategic perspective, companies that integrate diagnostic strategies, invest in robust real-world evidence programs, and engage payers proactively will be better positioned to achieve durable adoption. Regional differentiation requires tailored evidence packages and localized execution plans to accommodate varying regulatory and reimbursement landscapes. Collectively, these insights underscore that success in this therapeutic area hinges on coordinated efforts across clinical development, evidence generation, manufacturing, and payer engagement.

In closing, the evolving immunotherapy landscape presents substantial opportunities to improve patient outcomes, but realizing those gains requires disciplined strategy, operational resilience, and sustained collaboration among industry, clinicians, and health systems.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Cancer Type

  • 8.1. Cancer Type
    • 8.1.1. Non-Small Cell Lung Cancer
      • 8.1.1.1. Non-Squamous
      • 8.1.1.1.1. Adenocarcinoma
      • 8.1.1.1.2. Large Cell Carcinoma
      • 8.1.1.2. Squamous
    • 8.1.2. Small Cell Lung Cancer

9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel

  • 9.1. Hospital Pharmacy
  • 9.2. Online Pharmacy
  • 9.3. Retail Pharmacy
  • 9.4. Specialty Pharmacy

10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. With Chemotherapy
    • 10.1.2. With Targeted Therapy
  • 10.2. Monotherapy

11. Immune Checkpoint Inhibitors for Lung Cancer Market, by Mechanism Of Action

  • 11.1. CTLA-4 Inhibitor
  • 11.2. PD-1 Inhibitor
    • 11.2.1. Cemiplimab
    • 11.2.2. Nivolumab
    • 11.2.3. Pembrolizumab

12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy

  • 12.1. First Line
  • 12.2. Second Line
  • 12.3. Third Or Later

13. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User

  • 13.1. Ambulatory Surgical Centers
  • 13.2. Home Care Settings
  • 13.3. Hospitals
  • 13.4. Oncology Clinics

14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Immune Checkpoint Inhibitors for Lung Cancer Market

18. China Immune Checkpoint Inhibitors for Lung Cancer Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. AstraZeneca plc
  • 19.7. Bayer AG
  • 19.8. BeyondSpring Pharmaceuticals Inc.
  • 19.9. BioLineRx Ltd.
  • 19.10. BridgeBio Inc.
  • 19.11. Bristol-Myers Squibb Company
  • 19.12. Celgene Corporation
  • 19.13. F. Hoffmann-La Roche AG
  • 19.14. Genentech, Inc.
  • 19.15. IQVIA Inc.
  • 19.16. Jazz Pharmaceuticals
  • 19.17. Mirati Therapeutics Inc.
  • 19.18. Ono Pharmaceutical Co. Ltd
  • 19.19. Philogen S.p.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ADENOCARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LARGE CELL CARCINOMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SQUAMOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SMALL CELL LUNG CANCER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SPECIALTY PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH CHEMOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY WITH TARGETED THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CTLA-4 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CEMIPLIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NIVOLUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PEMBROLIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY THIRD OR LATER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY ONCOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 105. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 106. AMERICAS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 118. NORTH AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 128. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 129. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 130. LATIN AMERICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE, MIDDLE EAST & AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 164. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 165. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 166. MIDDLE EAST IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 176. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 177. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 178. AFRICA IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 188. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 189. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. ASIA-PACIFIC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GLOBAL IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 201. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 202. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 203. ASEAN IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 204. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 207. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 208. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 211. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 213. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 214. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 215. GCC IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 227. EUROPEAN UNION IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 237. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 238. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 239. BRICS IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 240. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 243. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 244. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 246. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 247. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 249. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 250. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 251. G7 IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY CANCER TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, 2018-2032 (USD MILLION)
  • TABLE 256. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY NON-SQUAMOUS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 258. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 259. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 261. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY PD-1 INHIBITOR, 2018-2032 (USD MILLION)
  • TABLE 262. NATO IMMUNE CHECKPOINT INHIBITORS FOR LUNG CANCER MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)